Barbara Klencke - 25 Feb 2026 Form 3 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)

Reporting relationship
Chief Medical Officer
Issuer ticker
ALXO
Reported as of
25 Feb 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
05 Mar 2026, 16:01:03 UTC
Prior SEC filing
19 Sep 2025
Next SEC filing
05 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Shelly Pinto, by power of attorney

Key filing fact

Barbara Klencke filed Form 3 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 05 Mar 2026.

Key facts

  • This page summarizes Barbara Klencke's Form 3 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
  • 0 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 05 Mar 2026, 16:01.

Change

  • Previous filing in this sequence was filed on 19 Sep 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001647647 Primary reporting owner

Klencke Barbara

Relationship
Chief Medical Officer
Address
C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Signature
/s/ Shelly Pinto, by power of attorney
Signature date
05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALXO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
60,000
Date
25 Feb 2026
Ownership
Direct
ALXO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
60,000
Date
25 Feb 2026
Ownership
See footnote
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALXO holding Derivative

Stock option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
25 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,400
Exercise price
$1.65
Footnotes
F2
ALXO holding Derivative

Stock option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
25 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
300,000
Exercise price
$1.05
Footnotes
F3
ALXO holding Derivative

Stock option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
25 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$1.48
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares are held directly by the reporting person's spouse.

Footnote F2

Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025.

Footnote F3

One-third of the shares subject to the option vest on each of September 17, 2025, January 31, 2026 and June 30, 2026.

Footnote F4

Shares subject to the option vest in 12 equal monthly installments beginning on February 26, 2026.

SEC remarks

Exhibit 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .